(AQB) AquaBounty Technologies, Inc. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AQB) AquaBounty Technologies, Inc. Complete Analysis Pack
Validate Every Claim with the Complete Sources File
This AquaBounty Technologies, Inc. SWOT Analysis helps you quickly assess the company’s strengths, weaknesses, opportunities, and threats for investing, strategy, or research; the page already contains a real preview/sample of the analysis so you can judge style and substance before buying—purchase the full version to receive the complete ready-to-use report.
Strengths
1991 founding and long operating history
AquaBounty Technologies, Inc., founded in 1991, brings more than 30 years of salmon genetics and aquaculture experience. That long run has helped it build know-how in breeding, fish health, and scaling operations from lab work to commercial farms. It also strengthens credibility with regulators and partners, since a 3-decade track record signals technical discipline and industry staying power.
2015 FDA approval for AquAdvantage salmon
AquaBounty Technologies, Inc. won a rare moat in 2015 when the U.S. FDA approved AquAdvantage salmon, the first genetically engineered animal cleared for human food. Health Canada also approved it, giving AquaBounty validation in 2 major markets and a regulatory edge few food companies can match. That approval still supports its brand, but the company ended 2025 with only about $1.7 million in cash, so the strength is strategic, not financial.
Integrated product mix of eggs fry salmon and byproducts
AquaBounty Technologies, Inc. sells AquAdvantage salmon, conventional Atlantic salmon, salmon eggs, juvenile fish, and byproducts, so it is not tied to one finished-fish line. That broader mix creates more revenue points across the chain, from hatchery inputs to harvest sales. In a small 2025 revenue base, that diversification matters because each product can help spread fixed farming costs.
R&D platform in genetics genomics fish health and nutrition
AquaBounty Technologies, Inc. built research across genetics, genomics, fish health, and nutrition, and that gave it one approved genetically engineered salmon line plus patent-backed know-how. In fish farming, even small gains in growth, survival, and feed use can move results fast, so this R&D base was a real moat.
The same platform also supported strain improvement and disease control, which can lower loss rates and improve output per tank. Over time, that kind of work can create intellectual property and licensing value, not just a better fish.
- Genetics and genomics improve strains.
- Fish health work cuts disease losses.
- Nutrition research can raise feed efficiency.
- One approved line supports IP value.
Land based aquaculture with faster growth cycle
AquaBounty Technologies, Inc.'s land-based AquAdvantage salmon reaches market size in about 18 months, versus roughly 3 years for conventional Atlantic salmon. That faster cycle can lift annual turnover, cut time-in-tank, and help the company produce more harvests from the same footprint.
Indoor systems also tighten control over water quality and biosecurity, which helps reduce disease risk, escapes, and weather exposure. The model is built for more predictable output, not just faster growth.
- 18 months vs 36 months to market size
- Shorter cycles improve turnover
- Land-based systems boost biosecurity
- Better control of water quality
AquaBounty’s FDA Moat and Fast-Growth Edge
AquaBounty Technologies, Inc. stands out for its first-mover FDA approval for AquAdvantage salmon and 30+ years of salmon genetics and aquaculture work. Its land-based system cuts time to market to about 18 months versus 36 months for conventional Atlantic salmon, while improving biosecurity and control. A broader product mix and patent-backed R&D add strategic depth. End-2025 cash was about $1.7 million.
| Strength | Key data |
|---|---|
| Regulatory moat | FDA approval in 2015; 2 major markets |
| Fast growth cycle | 18 months vs 36 months |
| Cash | About $1.7 million at end-2025 |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing AquaBounty Technologies, Inc.’s business strategy
Editable Excel File
Provides a quick AquaBounty Technologies SWOT snapshot to simplify strategic decision-making.
Reference Sources
Provides a concise, traceable bibliography of industry reports, regulatory filings, and scientific studies to validate AquaBounty’s market, production, and economic claims.
Weaknesses
Small commercial scale versus global salmon producers
AquaBounty Technologies, Inc. operates at a much smaller scale than global salmon leaders: Mowi harvested 502,000 tonnes in 2024, showing the gap in production depth. Smaller volume weakens buying power on feed, fish health inputs, and freight, so unit costs stay higher. It also leaves AquaBounty Technologies, Inc. less able to spread fixed plant and labor costs, which makes margins more volatile.
Heavy dependence on one flagship GMO product
AquaBounty Technologies, Inc. still leans almost entirely on AquAdvantage salmon, so any slowdown in approvals, sales, or farm scale-up hits the whole business. That kind of single-product concentration raises execution risk and leaves the company exposed to one GMO story, not a broader portfolio. With 2024 revenue still near zero and operating losses ongoing, even a small adoption miss can matter a lot.
Capital intensive land based farms
AquaBounty Technologies, Inc. relies on recirculating aquaculture systems that need heavy upfront spend on buildings, tanks, filtration, and power. This cost base can stay high before each farm reaches full output, so margins can stay weak during ramp-up. Expansion also lifts financing needs, since more land-based capacity means more cash tied up in fixed assets and working capital.
Regulatory and public acceptance burden
AquaBounty’s genetically engineered salmon faces more scrutiny than conventional seafood, so each market adds labeling, approval, and education costs. The FDA still treats it as the only approved genetically engineered animal for food in the U.S., but public pushback can still slow orders after approval.
That burden hit hard when AquaBounty reported only $0.3 million in revenue for 2024, showing that regulatory clearance did not translate into fast demand. Negative consumer perception can keep sales weak even when the product is legally cleared.
- Higher scrutiny than farmed salmon
- Approval does not ensure demand
- Labeling and education add cost
- Public distrust can delay sales
Limited internal cash generation
AquaBounty Technologies, Inc. has relied on external funding to cover operations and growth, which shows limited internal cash generation. Weak cash flow cuts flexibility in downturns or expansion cycles and can force costly financing. That dependence can dilute shareholders and raise financial risk when liquidity tightens.
- Needs outside capital to fund growth.
- Lower cash flow limits downturn flexibility.
- Financing can dilute shareholders.
- Liquidity pressure lifts risk.
AquaBounty’s tiny scale leaves it exposed to losses and funding risk
AquaBounty Technologies, Inc. remains a weak, small-scale player: 2024 revenue was only $0.3 million, versus Mowi’s 502,000 tonnes of salmon harvest in 2024, so unit costs stay high and fixed costs are hard to absorb. Its near-total dependence on AquAdvantage salmon, heavy recirculating-aquaculture capex, and ongoing losses leave it exposed to regulatory, demand, and funding risk.
| Weakness | Data point |
|---|---|
| Scale gap | 2024 revenue: $0.3 million |
| Single-product risk | One main salmon line |
| High fixed costs | RAS needs heavy capex |
| Funding strain | Ongoing losses, outside capital |
What You See Is What You Get
AquaBounty Technologies, Inc. Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and purchasing unlocks the complete, editable version with detailed strengths, weaknesses, opportunities, and threats for AquaBounty Technologies, Inc.
Opportunities
North American salmon demand growth
Salmon stays a strong protein choice in the U.S. and Canada, and U.S. seafood imports cover about 80% of demand. As seafood consumption keeps rising, domestic producers can win more volume by offering fresh, local supply with shorter transport times. AquaBounty Technologies, Inc. can target buyers that want traceable North American salmon instead of imported fish.
Import substitution in a seafood market led by foreign supply
North American salmon supply is still import-heavy, with more than 90% of U.S. seafood consumed coming from abroad and farmed salmon led by Canada, Chile, and Norway. A U.S. land-based producer like AquaBounty Technologies can cut transit time, reduce cold-chain risk, and deliver fresher fish. That can win retailers and foodservice buyers that want steadier supply and lower logistics exposure.
Licensing genetics and production know how
AquaBounty Technologies, Inc. could monetize its genetics and breeding know-how beyond direct farming by licensing it to third-party aquaculture operators. That would let the Company earn recurring fee or royalty income without owning every hatchery and grow-out asset. An asset-light model should improve capital efficiency and cut the cash tied up in fish production.
Premium for sustainable and traceable seafood
AquaBounty Technologies, Inc. can sell land-based salmon as controlled, traceable, and lower-pressure on wild fisheries. FAO said aquaculture supplied 57% of aquatic animal foods in 2022, so buyers already accept farmed supply; that supports a premium for verified sustainability and clean provenance.
- Controlled recirculating systems
- Traceability from egg to plate
- Premium appeal to buyers
Expansion into additional sites and partnerships
AquaBounty Technologies, Inc. can expand with new sites, joint ventures, or contract growing deals, which would let it add capacity without paying for every facility itself. That matters because its 2023 revenue was $2.4 million, so outside partners could speed scale faster than balance-sheet funding alone. Wider site access would also help it serve more of the U.S. and Canada.
- New sites can lift output faster.
- Joint ventures cut capital needs.
- Contract growers widen market reach.
AquaBounty’s Local Salmon Edge in an Import-Heavy U.S. Market
North American salmon demand still leaves room for a local producer: U.S. seafood imports cover about 80% of demand, and farmed salmon supply is led by Canada, Chile, and Norway. AquaBounty Technologies, Inc. can sell fresher, traceable fish with lower transport risk, while its genetics know-how can also earn licensing fees. Controlled land-based production fits buyers paying for stable supply and sustainability.
| Metric | Data |
|---|---|
| U.S. seafood imports | ~80% of demand |
| FAO aquaculture share | 57% in 2022 |
| AquaBounty Technologies, Inc. revenue | $2.4 million in 2023 |
Threats
Ongoing GE food regulation and approval risk
AquaBounty Technologies, Inc. faces high approval risk because GE food rules can shift by country and by administration, and genetically engineered seafood is still heavily scrutinized. AquAdvantage salmon is approved in the U.S. and Canada, but new review steps, delays, or import limits could slow growth plans and add compliance costs. Any tighter rule can hit sales fast, since regulatory clearance is the gate to market access.
Consumer and retailer resistance to GMO seafood
Consumer caution still weighs on AquaBounty Technologies, Inc.; GMO seafood faces skepticism even after approval, and only one genetically engineered salmon has cleared the U.S. FDA. Retailers can cut shelf space or skip orders, so a single negative headline can hit volume fast. In a category this small, even modest pullbacks can block scale.
Disease mortality and biosecurity failures
Disease, poor water quality, and contamination can wipe out a full crop fast, and one outbreak can still stop output even in land-based systems. AquaBounty Technologies, Inc. faces that risk because biosecurity failures can destroy inventory, raise mortality, and force costly shutdowns. In aquaculture, losses are not just biological; they quickly become cash burn and missed sales.
Salmon price volatility and low cost imports
Farmed salmon prices stay volatile because global supply, feed costs, and import flows can swing fast; USDA data show U.S. salmon imports were still near 95% of supply in recent years, so cheap foreign fish can reset pricing quickly. For AquaBounty Technologies, Inc., lower-priced conventional salmon from Norway, Chile, and Canada can weaken its premium story before scale lowers unit costs. That price gap can squeeze gross margin and cash burn in a market where retail salmon often trades around $9 to $15 per pound.
- Cheap imports pressure premium pricing
- Feed and supply swings move market prices
- Margins can compress before scale arrives
High energy feed and utility cost exposure
Recirculating aquaculture runs 24/7, so AquaBounty Technologies, Inc. is exposed to nonstop electricity, filtration, oxygenation, and water-management costs. Feed is still the largest variable cost in fish farming, and even a small jump in power prices can push margins down fast; a grid outage can also trigger immediate stock losses and facility downtime.
- 24/7 power need raises fixed costs
- Feed inflation hits margins fast
- Outages can cause instant production loss
AquaBounty Faces Regulation, Demand, and Cost Pressures
Threats to AquaBounty Technologies, Inc. center on regulation, demand, and unit economics: one rule change can block sales, while GMO seafood skepticism can still limit retail uptake. Cheap imported salmon keeps pressure on pricing, and the company may have to absorb higher feed, power, and biosecurity costs before scale helps margins.
| Risk | Data point |
|---|---|
| U.S. salmon imports | ~95% of supply |
| Retail salmon price | $9-$15/lb |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.